Glenmark Pharmaceuticals Ltd share price logo

Glenmark Pharmaceuticals Ltd

NSE: GLENMARK

BSE: 532296

Mid Cap

Pharma Sector

₹2475.00

+13.60

(+0.55%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Tech Chart

🔔 Regulatory News Alert

Glenmark Pharma's Goa manufacturing facility received US FDA Establishment Inspection Report with Voluntary Action Indicated status, indicating minor issues without regulatory action.

What are INDmoney investors doing with Glenmark Pharmaceuticals shares?

Based on platform-user behaviour - not analyst opinion or company fundamentals.

Search interest on INDmoney

-26%

Searches for Glenmark Pharmaceuticals on INDmoney have decreased by 26% over the last 30 days.

Among the most traded stocks

180th

Glenmark Pharmaceuticals was the 180th most traded stock on INDmoney over the last 7 days.

Average holding period of indmoney investors

23 days

INDmoney investors hold Glenmark Pharmaceuticals shares for an average of 23 days.

Key Events for Glenmark Pharmaceuticals

Last Dividend Declared

₹2.50 per share, declared on 29/05/2026

View Dividend History

Glenmark Pharmaceuticals Stock Performance

as on September 23, 2026 at 9:31 pm IST

  • Day's Low

    Day's High

    ₹2,453.60
    ₹2,482.60
    downward going graph

    0.86%

    Downside

    0.31%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    ₹1,792.60
    ₹2,537.60
    downward going graph

    27.57%

    Downside

    2.53%

    Upside

    downward going graph

Glenmark Pharmaceuticals share price movements today

Previous Close
₹2,461.40
Open
₹2,472.00
Volume
5.97L
Upper Circuit
₹2,547.90
Lower Circuit
₹2,399.50
Day's Low - High
₹2,453.60 - ₹2,482.60
52 Week Low - High
₹1,792.60 - ₹2,537.60

Glenmark Pharmaceuticals Historical Returns

1 Month Return
+ 2.96 %
3 Month Return
+ 12.94 %
1 Year Return
+ 22.04 %
3 Year Return
+ 213.33 %
5 Year Return
+ 380.74 %

Glenmark Pharmaceuticals Fundamentals

as on September 23, 2026 at 4:01 pm IST

Market Cap

₹69,466.78 Cr

Return on Equity (ROE)

3.87

PE Ratio (TTM)

38.63

Return on capital employed (ROCE)

6.3

Industry PE ratio

53.19

Beta (LTM)

0.84

P/B Ratio

2.49

Dividend Yield

0.23

PEG Ratio

1.04

Quarterly Earnings Growth YOY

927.95

EPS (TTM)

48.26

Book Value

372.51

Glenmark Pharmaceuticals Stock Valuation

as on September 23, 2026 at 4:01 pm IST

Glenmark Pharmaceuticals in the last 5 years

  • Overview

  • Trends

Lowest (-275.05x)

December 28, 2023

Today (38.63x)

September 22, 2026

Industry (53.19x)

September 22, 2026

Highest (95.94x)

September 14, 2023

LowHigh

Today’s Price to Earnings Ratio: 38.63x

Glenmark Pharmaceuticals Technical Analysis

Track how Glenmark Pharmaceuticals technical analysis has moved over time to understand its trends.

1 min
5 min
15 min
30 min
1 day
1 week
1 month

Technicals Summary

Bearish

Neutral

Bullish

Bullish

Moving Averages

Bearish

Neutral

Bullish

Bullish

Oscillators

Bearish

Neutral

Bullish

Neutral

Overall

Bearish1
Bullish10
Neutral4

Oscillators

Name

Value

Action

MACD level (12,26)
0.35
Bearish
CCI (20)
46.06
Neutral
RSI (14)
58.33
Neutral
Momentum (10)
0
Neutral
ADI (14)
56.21
Neutral
Ultimate Oscillator (7,14,28)
91.22
Bullish

Moving Averages

Name

Value

Action

SMA (20)
2474.7
Bullish
EMA (20)
2474.67
Bullish
VWMA (20)
2474.94
Bullish
SMA (50)
2474.03
Bullish
EMA (50)
2474.16
Bullish
SMA (200)
2470.6
Bullish
EMA (200)
2471.71
Bullish
KAMA (200)
2473.27
Bullish
DEMA (200)
2474.48
Bullish

Glenmark Pharmaceuticals Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Glenmark Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
Glenmark Pharmaceuticals Ltd image
Glenmark Pharmaceuticals Ltd
BUY69,466.7876.15%0.611,36116,982
Cohance Lifesciences Ltd image
Cohance Lifesciences Ltd
HOLD17,322.09-3.25%0.621502,268
Jubilant Pharmova Ltd image
Jubilant Pharmova Ltd
BUY17,058.6414.68%0.733978,279
Sun Pharma Advanced Research Company Ltd image
Sun Pharma Advanced Research Company Ltd
NA6,424.23-6.35%0.661,5531,879
Rainbow Childrens Medicare Ltd image
Rainbow Childrens Medicare Ltd
BUY14,533.1743.57%0.682811,703
See all

Market expectation of Glenmark Pharmaceuticals Stock

Common consensus of the market based on various publicly available news, publications,brokerage expectation and market data

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Glenmark Pharmaceuticals Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sales
3,160.69
2,460.29
3,016.01
3,223.3
3,400.5
3,301.9
3,220.13
3,059.33
6,003.79
3,888
3,760.28
3,931.73
Other Income
120.43
164.18
797.54
31.49
39.42
31.13
11.69
26.44
200.63
44.47
189.08
65.76
Total Income
3,327.81
2,670.88
3,860.49
3,275.68
3,473.21
3,418.68
3,267.89
3,290.88
6,247.5
3,945.08
3,959.67
4,084.25
Expenses
3,070.52
2,792.07
3,005.39
2,655.97
2,831.88
2,787.32
3,068
3,007.15
5,072.44
3,215.2
3,381.39
3,213.69
Operating Profit
90.17
-331.78
10.62
567.33
568.62
514.58
152.13
52.18
931.35
672.8
378.89
718.04
Operating Profit Margin %
2.85%
-13.49%
0.35%
17.6%
16.72%
15.58%
4.72%
1.71%
15.51%
17.3%
10.08%
18.26%
Profit Before Interest, Tax and Depreciation
257.3
-121.2
855.1
619.71
641.33
631.36
199.89
283.73
1,175.06
729.88
578.28
870.56
Interest
121.46
134.34
148.56
39.58
48.48
52.29
66.71
58.23
66.46
41.43
42.6
54
Depreciation
141.45
147.08
151.34
117.79
120.28
122.74
125.21
129.93
141.2
154.45
147.91
173.17
Profit Before Tax
-5.61
-402.62
555.2
462.34
472.57
456.33
7.97
95.57
967.4
534
387.77
643.39
Tax Paid
55.95
-71.8
1,769.47
122.09
118.09
108.29
3.59
48.6
356.97
130.77
86.45
160.56
Profit After Tax
-61.56
-330.82
-1,214.27
340.24
354.49
348.03
4.38
46.97
610.43
403.23
301.32
482.83
Total Net profit including share of profit / Loss from associate company
-61.56
-330.82
-1,214.27
340.24
354.49
348.03
4.38
46.97
610.43
403.23
301.32
482.83
EPS
-2.9
-12.45
-43.17
12.06
12.55
12.33
0.16
1.66
21.63
14.29
10.68
17.11
Actual EPS
-2.9
-12.45
-43.17
12.06
12.55
12.33
0.16
1.66
21.63
14.29
10.68
17.11
Adjusted EPS
-2.9
-12.45
-43.17
12.06
12.55
12.33
0.16
1.66
21.63
14.29
10.68
17.11
Diluted EPS
-2.9
-12.45
-43.17
12.06
12.55
12.33
0.16
1.66
21.62
14.28
10.68
17.11

Glenmark Pharmaceuticals Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Sales
8,972.23
9,705.08
10,397.23
10,806.03
12,174.2
11,431.94
11,635.46
13,145.84
16,711.4
Other Income
91.4
375.32
192.48
94.76
166.67
755.86
1,237.32
113.72
460.62
Total Income
9,194.47
10,240.79
10,833.45
11,038.69
12,471.58
12,339.1
13,050.42
13,435.46
17,443.13
Expenses
7,487.7
8,279.67
8,942.89
8,859.55
10,245.52
10,714.08
11,518.72
11,343.18
14,676.18
Operating Profit
1,484.53
1,425.41
1,454.34
1,946.48
1,928.68
717.86
116.74
1,802.66
2,035.22
Operating Profit Margin %
16.55%
14.69%
13.99%
18.01%
15.84%
6.28%
1%
13.71%
12.18%
Profit Before Interest, Tax and Depreciation
1,706.77
1,961.12
1,890.56
2,179.14
2,226.06
1,625.01
1,531.7
2,092.28
2,766.95
Interest
285.57
334.59
377.32
353.11
298.1
349.04
515.97
207.07
208.73
Depreciation
301.88
325.91
417.17
443.55
486.72
569.17
581.91
486.01
573.48
Profit Before Tax
1,119.32
1,300.62
1,096.07
1,382.48
1,441.24
706.8
433.82
1,399.2
1,984.74
Tax Paid
315.46
375.63
320.11
412.39
447.6
329.4
1,867.34
352.07
622.8
Profit After Tax
803.87
924.99
775.97
970.09
993.65
377.4
-1,433.52
1,047.14
1,361.95
Total Net profit including share of profit / Loss from associate company
803.87
924.99
775.97
970.09
993.65
377.4
-1,433.52
1,047.14
1,361.95
EPS
28.49
32.78
27.5
34.38
33.37
10.53
-53.22
37.11
48.26
Actual EPS
28.49
32.78
27.5
34.38
33.37
10.53
-53.22
37.11
48.26
Adjusted EPS
28.49
32.78
27.5
34.38
33.37
10.53
-53.22
37.11
48.26
Diluted EPS
28.49
32.78
27.5
34.38
33.37
10.53
-53.22
37.1
48.24

Glenmark Pharmaceuticals Ltd Cash Flow

Figures in Rupees Crores

Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Net Cash from Operating Activities
344.85
657.43
1,648.05
1,324.17
1,392.41
1,131.21
1,108.65
625.39
-265.44
-827.6
3,445.03
Cash Flow from Investing Activities
-950.06
-1,001.34
-1,002.56
-882.52
-773.75
-661.62
-315.74
-515.43
4,386.81
58
-1,237.28
Cash Flow from Financing Activities
698.6
543.14
-468.49
-738.74
-444.65
-441.78
-463.11
75.27
-3,906.13
787.04
-2,708.75
Net Cash Flow
93.39
199.24
176.99
-297.08
174
27.82
272.43
32.5
215.24
17.44
-501

Glenmark Pharmaceuticals Stock Shareholding Pattern

Numbers in percentages

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Promoters
46.65%
46.64%
46.65%
46.65%
46.65%
46.65%
46.65%
46.65%
46.65%
46.65%
46.65%
DII
10.92%
13.36%
13.92%
13.21%
13.85%
14.6%
17.64%
18.61%
20.09%
19.29%
18.6%
FII
23.71%
21.38%
20.98%
23.05%
23.51%
23.16%
20.62%
20.73%
19.2%
20.34%
20.89%
Government
0.04%
0.04%
0.04%
0.04%
0.04%
0.04%
0.04%
0.04%
0.04%
0.04%
0.04%
Public
18.69%
18.58%
18.41%
17.06%
15.96%
15.56%
15.06%
13.97%
14.02%
13.68%
13.81%
Total Outstanding Shares
28,21,68,156
28,21,88,156
28,21,88,156
28,21,88,156
28,21,88,156
28,21,88,156
28,22,00,809
28,22,00,809
28,22,00,809
28,22,00,809
28,22,00,809
Total Shareholders
2,09,931
1,99,451
1,92,630
1,93,949
1,95,059
1,92,724
1,90,210
1,98,789
2,01,584
1,96,105
2,11,418

Glenmark Pharmaceuticals Corporate Actions

View detailed summary of the earnings and dividend history of Glenmark Pharmaceuticals.

  • Glenmark Pharmaceuticals Ltd Earnings Results

    Glenmark Pharmaceuticals Ltd’s net profit jumped 930.34% since last year same period to ₹482.92Cr in the Q1 2026-2027. On a quarterly growth basis, Glenmark Pharmaceuticals Ltd has generated 60.22% jump in its net profits since last 3-months.

    Read More about Earnings Results

  • Glenmark Pharmaceuticals Ltd Dividends May,2026

    In the quarter ending March 2026, Glenmark Pharmaceuticals Ltd has declared dividend of ₹2.50 per share on 29 May 2026 - translating a dividend yield of 0.20%.

    Read More about Dividends

Indices Featuring Glenmark Pharmaceuticals Stock

Check stock indices that include Glenmark Pharmaceuticals.

S&P BSE Momentum

₹2,206.16

+20.03 (▲0.92%)

NIFTY PHARMA

₹27,152.10

+242.50 (▲0.90%)

Nifty 500

₹22,935.10

+140.90 (▲0.62%)

Nifty 200

₹13,695.95

+82.55 (▲0.61%)

S&P BSE MidCap Select

₹18,743.48

+146.43 (▲0.79%)

BSE 500

₹35,870.78

+198.74 (▲0.56%)

Nifty Alpha 50

₹55,885.85

+419.70 (▲0.76%)

Nifty Healthcare

₹16,868.15

+148.15 (▲0.89%)

Nifty LargeMidcap 250

₹16,432.75

+98.40 (▲0.60%)

Nifty Midcap 150

₹22,928.85

+141.65 (▲0.62%)

S&P BSE 250 LargeMidCap

₹10,569.04

+57.33 (▲0.55%)

S&P BSE 150 MidCap

₹16,967.16

+106.22 (▲0.63%)

Nifty Midcap 100

₹62,396.45

+433.30 (▲0.70%)

Nifty MidSmallcap 400

₹21,304.80

+146.50 (▲0.69%)

BSE Healthcare

₹52,142.02

+427.51 (▲0.83%)

S&P BSE 400 MidSmallCap

₹12,753.29

+80.75 (▲0.64%)

Insights on Glenmark Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 301.41 Cr → 482.92 Cr (in ₹), with an average increase of 37.6% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, GLENMARK stock has moved up by 213.3%

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 20.35% to 20.89% in Jun 2026 quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 13.68% to 13.81% in Jun 2026 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 3.94K Cr → 4.08K Cr (in ₹), with an average increase of 1.7% per quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 46.65% of holdings in Jun 2026 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 54.6% return, outperforming this stock by 32.5%

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 16.80% to 16.76% in Jun 2026 quarter

Glenmark Pharmaceuticals Stock Futures & Options Contracts

View the latest movement in Glenmark Pharmaceuticals Futures & Options, including strike prices, expiry dates, and percentage changes.

Glenmark Pharmaceuticals Options

Name
Expiry
Strike Price
LTP
Absolute Change
Change
GLENMARK 29 Sep ₹2460 Call
September 29, 2026
₹2460
₹36.95
5.25
16.56%
GLENMARK 29 Sep ₹2480 Call
September 29, 2026
₹2480
₹26.7
3.5
15.09%
GLENMARK 29 Sep ₹2500 Call
September 29, 2026
₹2500
₹18.05
1.6
9.73%
GLENMARK 29 Sep ₹2720 Call
September 29, 2026
₹2720
₹1.4
0.15
12%

Glenmark Pharmaceuticals Futures

Name
Expiry
Strike Price
LTP
Absolute Change
Change
GLENMARK 29 Sep Fut
September 29, 2026
-
₹2482.9
23.85
0.97%
GLENMARK 27 Oct Fut
October 27, 2026
-
₹2495
22.75
0.92%
GLENMARK 23 Nov Fut
November 23, 2026
-
₹2505
25.78
1.04%

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is an Indian pharmaceuticals company listed on the National Stock Exchange and Bombay Stock Exchange. Established in 1977, the company manufactures and distributes branded and generic formulations, active pharmaceutical ingredients (API’s) and biosimilars. It has 18 manufacturing facilities in India, 7 in the U.S., 1 in Brazil and 1 in Mexico that span across the world catering to global requirements. Glenmark has taken several steps towards achieving a healthy presence in the global markets. In addition to its product portfolio, Glenmark’s aggressive acquisition strategy and product launch activities have helped expand its market reach. The company has been awarded numerous accolades over the years, including consecutive years of being ranked amongst the top 1000 world pharmaceutical companies. It continues to be a frontrunner in providing quality and affordable healthcare solutions in India and abroad.

Revenue: ₹3,931.73Cr as on June 2026 (Q1 FY27)
Net Profit: ₹482.83Cr as on June 2026 (Q1 FY27)
Listing date: 07 Feb, 2000
Chairperson Name: Glenn Saldanha
OrganisationGlenmark Pharmaceuticals Ltd
HeadquartersMumbai
IndustryPharmaceuticals
CEOGlenn Saldanha
E-voting on sharesClick here to vote

FAQs

What is Glenmark Pharmaceuticals share price today?

Glenmark Pharmaceuticals share price today stands at ₹2475 as on at the close of the market. Glenmark Pharmaceuticals share today touched a day high of ₹2482.6 and a low of ₹2453.6.

What is the 52 week high and 52 week low range for Glenmark Pharmaceuticals share?

Glenmark Pharmaceuticals touched a 52 week high of ₹2537.6 and a 52 week low of ₹1792.6. Glenmark Pharmaceuticals share price today i.e. is closed at ₹2475, which is -2.47% down from its 52 week high and 38.07% up from its 52 week low.

What is Glenmark Pharmaceuticals's market capitalisation today?

Glenmark Pharmaceuticals market capitalisation is ₹69,466.78 Cr as on .

How to buy Glenmark Pharmaceuticals shares?

To buy Glenmark Pharmaceuticals shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for GLENMARK or Glenmark Pharmaceuticals Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Glenmark Pharmaceuticals shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Glenmark Pharmaceuticals trading volume today?

Glenmark Pharmaceuticals trading volume is 5.97L as on . This means that 5.97L shares of Glenmark Pharmaceuticals were bought and sold on the stock market during today's trading session.